Metabolic · Lyophilized Powder
CAS: 910463-68-2 | Sequence: 31-aa acylated GLP-1 analogue | Purity: ≥99.3%
$59.99 / vial
In Stock - Ships Within 24 Hours
SKU PT-SEMA-5 · HPLC + MS tested every batch · Insulated cold-pack shipping
Semaglutide is a long-acting analogue of human glucagon-like peptide-1, GLP-1(7–37), engineered for resistance to enzymatic degradation and for reversible binding to serum albumin. The 31-residue peptide (4113.58 g/mol) carries an Aib substitution at position 8, arginine at position 34, and a C18 fatty diacid attached to Lys26 through a γGlu–2×OEG linker.
Together these modifications extend its half-life from minutes, for native GLP-1, to roughly one week, making semaglutide a standard reference compound for GLP-1 receptor pharmacology, incretin signalling, islet biology and central appetite-regulation research.
Supplied as 5 mg of lyophilized reference material at ≥99.3% HPLC purity with a batch-specific third-party COA. This is research-grade material, not a drug product — see the regulatory note in the Preclinical Research tab.
Each production lot is independently tested for identity, purity and content. Select a batch to view its analytical results — your vial label lists the batch number.
| Test | Method | Result | Status |
|---|
Technical reference data and a summary of published preclinical literature, provided for educational purposes.
| Name | Semaglutide |
|---|---|
| Synonyms | NN9535, NNC 0113-0217 |
| CAS Number | 910463-68-2 |
| Molecular Formula | C187H291N45O59 |
| Molecular Weight | 4113.58 g/mol |
| Sequence (3-letter) | H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(γGlu-2×OEG-C18 diacid)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH |
| Sequence (1-letter) | H-H(Aib)EGTFTSDVSSYLEGQAAK(γE-2xOEG-C18 diacid)EFIAWLVRGRG-OH |
| Structure Class | Acylated GLP-1(7–37) analogue: Aib8 and Arg34 substitutions, Lys26 side chain derivatized with a C18 fatty diacid via a γGlu–2×OEG linker |
| Form | White lyophilized powder |
| Purity | ≥99.3% (RP-HPLC); identity confirmed by ESI-MS |
| Content per Vial | 5 mg net peptide |
| Solubility | Soluble in water and bacteriostatic water; solubility is reduced under acidic conditions |
| Storage Conditions | Lyophilized: −20 °C, desiccated and protected from light. Reconstituted: 2–8 °C, use within 28 days. Swirl gently after reconstitution; acylated peptides are prone to aggregation under vigorous agitation. |
Semaglutide shares roughly 94% sequence homology with native human GLP-1 and is a full agonist of the GLP-1 receptor, driving cAMP signalling, glucose-dependent insulin secretion and glucagon suppression in islet and cell-line models.
Aib at position 8 confers resistance to DPP-4 cleavage, and the C18 fatty diacid side chain promotes reversible albumin binding, reducing renal clearance. The discovery program reported an elimination half-life of roughly one week in humans.
Rodent studies using labelled semaglutide show access to circumventricular and hypothalamic regions, including the arcuate nucleus, with downstream effects on neural pathways associated with food intake.
In pancreatic islet and β-cell models, GLP-1 receptor activation by semaglutide raises intracellular cAMP and potentiates insulin secretion only at elevated glucose concentrations, a glucose dependence central to incretin research. Diet-induced obese rodent models are widely used to study its effects on food intake and body-weight regulation.
Semaglutide is also studied in oral peptide-delivery research: co-formulation with the absorption enhancer SNAC was shown to promote local, pH-buffered absorption across the gastric epithelium.
Unlike most compounds in our catalog, semaglutide has extensive randomized clinical trial data, including the STEP program. That literature concerns the approved pharmaceutical products, not research-grade material.
Representative literature: Lau J et al., J Med Chem 2015; Gabery S et al., JCI Insight 2020; Wilding JPH et al., N Engl J Med 2021; Buckley ST et al., Sci Transl Med 2018.
| Diluent Added | Concentration | Per 0.1 mL Aliquot |
|---|---|---|
| 1.0 mL | 5.0 mg/mL | 500 µg |
| 2.0 mL | 2.5 mg/mL | 250 µg |
| 2.5 mL | 2.0 mg/mL | 200 µg |
| 3.0 mL | 1.67 mg/mL | 167 µg |
| 5.0 mL | 1.0 mg/mL | 100 µg |
Allow the vial to reach room temperature. Introduce sterile or bacteriostatic water slowly down the inner glass wall — do not inject directly onto the powder cake. Swirl gently until fully dissolved; do not shake or vortex, as this can promote aggregation.
| State | Condition | Typical Stability |
|---|---|---|
| Lyophilized | −20 °C, desiccated | 24+ months |
| Lyophilized | 2–8 °C | Up to 12 months |
| Lyophilized | Room temp (≤25 °C) | Several weeks (transit) |
| Reconstituted | 2–8 °C | Up to 28 days |
| Reconstituted | −20 °C aliquots | Avoid repeated freeze–thaw |
Quality & Analytics
What a chromatogram, a purity percentage and a mass spectrum actually tell you — and the red flags that suggest a Certificate of Analysis deserves a closer look.
Storage & Stability
How peptides degrade, why −20 °C and desiccation matter, and practical rules for freeze–thaw cycles, light exposure and reconstituted shelf-life.
Research Review
Single versus dual incretin agonism: how the two most studied incretin analogues differ in structure, receptor signalling and handling — and what that means for assay design.
Complementary research compounds and lab supplies.